Peptide cycling claims on TikTok: what the science says

What did @pep.tide.glow.up actually say?

The creator argued that "cycling on peptides is crucial" because "your body gets used to things" and "when you don't cycle, results stop, receptors downregulate, and risks go up." They used NAD+ as a specific example, recommending six to eight weeks on followed by a break. The framing was that cycling is a kind of physiological reset, like a rest day.

To their credit, they were upfront about their limits. Ten months of personal use does not make someone a clinical authority, and they said so. The disclaimer was genuine, not just legal boilerplate. That matters when you're talking to an audience that may be sourcing peptides without a prescription or medical oversight.

The core message, that continuous use of certain compounds warrants periodic breaks, is not unreasonable. But the specific mechanisms they named deserve more scrutiny than a TikTok caption allows.

Does the science back this up?

Partially, but not in the clean, universal way the video implies. Receptor desensitization is a real phenomenon, but it is compound-specific, dose-dependent, and not well-characterized for most of the peptides discussed in this category.

For growth hormone secretagogues like ipamorelin and CJC-1295, there is legitimate research showing that continuous stimulation of the GHRH receptor can blunt GH pulse amplitude over time. A study by Popovic et al. (2019, Growth Hormone and IGF Research) noted attenuated responses with sustained GHRH receptor agonism in animal models. That is a reasonable basis for cycling those specific peptides.

NAD+ is not a peptide. It is a coenzyme. Including it as an example in a video about peptide cycling is a category error. The evidence for cycling NAD+ precursors like NMN or NR is largely theoretical and not supported by robust clinical trial data in humans as of 2024.

For peptides like BPC-157 or TB-500, there is almost no human clinical trial data on cycling protocols at all. The receptor downregulation argument, applied broadly, outpaces the evidence.

What did they get wrong or right?

They got the general instinct right: continuous, unmonitored use of compounds that affect endocrine signaling is not obviously safe, and taking breaks is a conservative, reasonable default. That is not bad advice for a general audience.

What they got wrong is the mechanism claim. Saying receptors downregulate as a universal consequence of peptide use implies a level of pharmacological consistency across these compounds that does not exist. BPC-157 acts through different pathways than ipamorelin, which acts through different pathways than GHK-Cu. Lumping them under one "cycling prevents downregulation" umbrella is an oversimplification.

The NAD+ error is worth naming plainly. NAD+ is repeatedly invoked in peptide communities as if it belongs in that category. It does not. Conflating it with peptide cycling muddies the actual pharmacology and could lead someone to apply inappropriate cycling logic to an entirely different class of compound.

• Receptor desensitization: real for some peptides, not established for all
• NAD+ is not a peptide, its inclusion as an example is inaccurate
• "Risks go up" without cycling: plausible for secretagogues, unsubstantiated as a blanket claim
• The general principle of cycling: reasonable, defensible, appropriately caveated

What should you actually know?

If you are using or considering peptides that affect growth hormone signaling, like ipamorelin or CJC-1295, the cycling logic has more support behind it than for other compounds. The GHRH axis has well-documented feedback mechanisms, and there is reason to think sustained stimulation affects sensitivity over time.

For peptides with less characterized receptor interactions, like BPC-157 or selank, cycling recommendations are largely based on community convention and precaution, not clinical data. That does not make them wrong. It means you should not confuse convention with evidence.

No cycling protocol, regardless of what TikTok says, substitutes for monitoring. If you are using peptides under medical supervision, labs like IGF-1, fasting glucose, and relevant hormonal panels are how you actually know whether something is working or causing problems. A break on a calendar is not a safety mechanism on its own.

Finally, ten months of personal experience is a starting point for curiosity, not a basis for mechanistic claims. The creator seems to understand this about themselves. The audience should too.